The presented in vitro and in vivo preclinical studies both demonstrated that isoliquiritigenin (ISL) efficiently suppressed endometrial cancer cell migration and reduced the HEC-1A-LUC tumor metastasis in nude mice by inhibiting the TGF-β/Smad signaling pathway. The gene discussed is TGFB1; the disease is neoplasm.